ArticleMaturitas2010
Cognitive changes associated with endocrine therapy for breast cancer.
Article in Maturitas, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Cognitive impairment following breast cancer treatments: an umbrella review.The oncologist · 2024Pooled it
- Trial
- Neuroimmunology of the female brain across the lifespan: Plasticity to psychopathology.Brain, behavior, and immunity · 2019Review
- International Cognition and Cancer Task Force Recommendations for Neuroimaging Methods in the Study of Cognitive Impairment in Non-CNS Cancer Patients.Journal of the National Cancer Institute · 2018Article
- Cognitive Effects of Aromatase and Possible Role in Memory Disorders.Frontiers in endocrinology · 2018Review
- Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).Breast cancer research and treatment · 2017Article
- Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol.BMC cancer · 2017Article
- Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients.Current opinion in supportive and palliative care · 2017Review
- Self-rated cognitive functions following chemotherapy in patients with breast cancer: a 6-month prospective study.Neuropsychiatric disease and treatment · 2017Article
- Prevalence of perceived cognitive dysfunction in survivors of a wide range of cancers: results from the 2010 LIVESTRONG survey.Journal of cancer survivorship : research and practice · 2016Article
- Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions.EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2014Article
- Chemotherapy-related changes in cognitive functioning.EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2013Review
- Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study.Brain, behavior, and immunity · 2013Article
- Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Article
- Why, After Chemotherapy, is it Necessary to Assess Memory Using Translational Testing?Breast cancer : basic and clinical research · 2012Article
- Breast cancer medications and vision: effects of treatments for early-stage disease.Current eye research · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Endocrine therapy in the setting of breast cancer has undoubtedly advanced clinical outcomes in this disease, but treatment with endocrine therapy is accompanied by a wide spectrum of side effects. It is of prime importance to understand and characterize these toxicities to facilitate clinical decision-making. Somewhat surprisingly, there is a relative paucity of data pertaining to cognitive changes associated with endocrine therapy. In this article we review cognitive associated with two classes of endocrine therapy: (1) selective estrogen receptor modulators (SERMs; tamoxifen and raloxifene) and (2) aromatase inhibitors (AIs; anastrozole, letrozole, and exemestane). Companion studies to the Multiple Outcome of Raloxifene Evaluation (MORE), the Study of Tamoxifen and Raloxifene (STAR) and National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 trials provide relevant data to understand the effect of SERMs on cognition. In contrast, substudies of the Arimidex, Tamoxifen Alone or in Combination (ATAC), Tamoxifen and Exemestane Adjuvant Multinational (TEAM) and Breast International Group (BIG) 1-98 trials juxtapose cognitive effects of AIs against those of tamoxifen. These and other studies are examined herein to provide a comprehensive overview of the effect of endocrine therapy on cognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.